Sarepta Therapeutics market cap SRPT
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $1.9B
- Highest close in our data
- $15.2B
- Jun 2024
Sarepta Therapeutics is worth $1.9B at the close on Nov 2, 2026, at $18.32 a share.
That is up 5% over the last year and down 75% over five years.
Its highest close in our data was $15.2B in Jun 2024.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.9B | $1.6B | $2.5B | −17% |
| 2025 | $2.3B | $1.2B | $12.1B | −80% |
| 2024 | $11.6B | $9.1B | $15.2B | +29% |
| 2023 | $9B | $7.3B | $13.9B | −21% |
| 2022 | $11.4B | $5.5B | $11.4B | +45% |
| 2021 | $7.8B | $5.3B | $8B | −42% |
| 2020 | $13.5B | $6.8B | $13.8B | +39% |
| 2019 | $9.7B | $5.6B | $11.6B | +34% |
| 2018 | $7.2B | $3.5B | $10.7B | +100% |
| 2017 | $3.6B | $1.5B | $3.7B | +140% |
| 2016 | $1.5B | $537.8M | $2.9B | −14% |
| 2015 | $1.7B | $495.7M | $1.7B | +204% |
| 2014 | $575M | $545.7M | $1.4B | −23% |
| 2013 | $744.1M | $540.1M | $1.8B | +23% |
| 2012 | $605.5M | $81.7M | $776M | +495% |
| 2011 | $101.8M | $76M | $181.9M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Sarepta Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| SRPTSarepta Therapeutics | $1.9B |
| HRMYHarmony Biosciences | $2.2B |
| ANIPANI Pharmaceuticals | $1.6B |
| PBHPrestige Consumer Healthcare | $2.4B |
| PAHCPhibro Animal Health | $1.6B |
| PCRXPacira BioSciences | $1.5B |
| ANABAnaptysbio | $1.4B |
| NRIXNurix Therapeutics | $2.8B |
| OMEROmeros | $1.3B |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OGNOrganon | $3.6B |
| Peer median | $1.6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Sarepta Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.